Why the study?
Does adenosine reduce LPS-induced TNF-alpha secretion in left ventricular muscle strips from patients with end-stage heart failure?
Does adenosine reduce LPS-induced TNF-alpha secretion in left ventricular muscle strips from patients with end-stage heart failure?
Adenosine and its analogs significantly inhibit TNF-alpha release in failing human heart tissue, suggesting a potential pharmacological target for heart failure.
Answers are grounded in this paper and cite their sources.
Should not yet change HF practice; leaves open adenosine signaling as anti-TNF target in human myocardium.
BACKGROUND: The proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) has been implicated in the pathogenesis of congestive heart failure. Recent studies have shown that adenosine inhibits lipopolysaccharide (LPS)-induced expression of TNF-alpha in macrophages and rat cardiomyocytes. The aim of this study was to determine whether adenosine has a similar effect in the failing human heart. METHODS AND RESULTS: Left ventricular muscle strips were obtained from seven patients with end-stage congestive heart failure undergoing heart transplantation or insertion of a left ventricular assist device. The muscle strips were incubated at 37 degrees C in 95% O2/5% CO2 and stimulated with LPS (10 microg/mL). TNF-alpha release in the supernatant was measured with ELISA, and muscle sections were stained for TNF-alpha. Muscle strips released TNF-alpha in the absence of LPS (0.22+/-0.05 pg x mL(-1) x mg wet wt[-1]). TNF-alpha was immunolocalized to the cardiac myocyte, suggesting that the myocyte is a source for TNF-alpha production. Adenosine (10 micromol/L) decreased TNF-alpha by 40% (P<.05). The selective adenosine A2 receptor agonist DPMA (10 micromol/L) decreased TNF-alpha release by 87% (P<.001), whereas ITu (10 micromol/L), an adenosine-regulating agent that increases endogenous adenosine concentration, inhibited TNF-alpha release by 93% (P<.001). CONCLUSIONS: Adenosine can significantly diminish TNF levels in the failing human heart and may represent a new pharmacological intervention in congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Wagner et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: